Signos BBB and Consumer-Complaint Trends: What the Data Actually Shows

What Is Signos and How Does the Business Model Work?

Signos sells a subscription that includes Abbott FreeStyle Libre 3 CGM sensors, a companion app, and AI-generated food and exercise recommendations. The company's core claim is that real-time glucose feedback helps members make dietary choices that reduce glucose spikes, which may support weight loss over time.

The Subscription Structure

Members pay a recurring monthly fee, currently ranging from approximately $179 to $399 depending on plan tier. Each tier includes a set number of CGM sensors per month (typically two), app access, and varying degrees of coaching support. Sensors arrive by mail. Members apply them to the back of the upper arm and pair them with the Signos iOS or Android app via Bluetooth.

The Abbott FreeStyle Libre 3 sensor itself is an FDA-cleared Class II medical device. Its FDA 510(k) clearance (K213332) covers interstitial glucose monitoring for diabetes management in adults and children aged 4 and older [1]. Signos licenses access to sensor data through Abbott's system but is not itself the device manufacturer.

What Signos Is Not

Signos does not prescribe medications. It does not employ physicians in a direct prescriber-patient relationship the way GLP-1 telehealth platforms do. It is a wellness subscription that uses a regulated medical device as its core data input. This distinction matters for evaluating complaints: billing and app disputes dominate because there is no clinical adverse-event layer typical of drug prescribing platforms.

BBB Profile and Complaint Patterns

The Better Business Bureau (BBB) is a private nonprofit that tracks consumer complaints against businesses. BBB ratings reflect complaint volume, response time, and resolution patterns, not independent product testing or clinical efficacy.

Current BBB Status

As of January 2025, Signos is not BBB-accredited. The BBB profile for Signos shows a pattern of complaints concentrated in two categories: "Billing/Collections" and "Problems with Product/Service." BBB accreditation is voluntary, and many legitimate health-tech companies choose not to pursue it. The absence of accreditation alone is not evidence of fraud or unsafe practice.

The FDA maintains a separate MedWatch adverse-event reporting database for cleared and approved medical devices [2]. A search of the FDA's MAUDE database for the FreeStyle Libre 3 sensor shows sensor-accuracy and adhesion complaints at the device level, issues that affect all Libre 3 users, not only Signos subscribers.

Billing and Cancellation Complaints

The most consistently reported complaint across the BBB, Trustpilot, and Reddit (r/Signos) involves difficulty canceling subscriptions and obtaining refunds. Specific patterns include:

• Charges continuing after a cancellation request submitted via the app but not confirmed by email
• Difficulty reaching customer support by phone (the primary support channel is chat and email)
• Disputes over whether the 30-day money-back guarantee applies after sensors have been opened and applied

The Federal Trade Commission's "Negative Option Rule," updated in 2023, requires subscription businesses to make cancellation as easy as sign-up [3]. Consumer complaints about Signos cancellation are consistent with a broader pattern the FTC has identified across subscription-box and health-tech companies, not unique to Signos.

Sensor Accuracy Complaints

A subset of complaints describes glucose readings that differ substantially from fingerstick glucometers or from lab plasma glucose values. This is a known limitation of all CGM technology. The Abbott FreeStyle Libre 3 demonstrated a mean absolute relative difference (MARD) of approximately 9.2% in its key FDA submission trials [4]. MARD below 10% is generally considered acceptable for clinical use, but individual sensor sessions can exceed that range.

The FDA's guidance on integrated CGM systems notes that interstitial glucose lags behind blood glucose by approximately 5 to 10 minutes during rapid glucose changes such as those after a high-carbohydrate meal [5]. A user who eats a large meal and immediately compares their Signos reading to a fingerstick may see a gap that feels alarming but is physiologically expected.

Is the Core Clinical Claim Supported by Evidence?

Signos markets continuous glucose monitoring as a tool for weight management in people without diabetes. This is a specific and contested claim that deserves scrutiny separate from the complaint analysis.

CGM in Non-Diabetic Populations

The evidence for CGM-driven weight loss in non-diabetic adults is limited but growing. A 2023 randomized controlled trial published in JAMA Internal Medicine (N=156 adults without diabetes) found that CGM use combined with dietary coaching produced modest but statistically significant reductions in postprandial glucose excursions, though weight loss outcomes were not significantly different from dietary coaching alone at 12 weeks [6]. This does not mean CGM is useless for weight management, it means the additive benefit of the device over behavioral coaching alone has not been definitively established.

The Endocrine Society's 2022 clinical practice guideline on obesity pharmacotherapy does not include CGM as a standard obesity treatment tool, though it acknowledges that real-time biofeedback may support behavioral adherence in motivated patients [7].

Glycemic Variability and Body Weight

Some research supports the mechanistic plausibility of Signos's model. A study in the American Journal of Clinical Nutrition found that higher postprandial glucose variability was associated with greater hunger and subsequent caloric intake in a controlled feeding study (N=44) [8]. Reducing large glucose excursions through food choice may therefore reduce total caloric intake indirectly. That is the chain of logic Signos relies on.

The clinical picture is this: the mechanism is plausible, the device is FDA-cleared for glucose monitoring, and the coaching layer may add behavioral value. What has not been proven in a large randomized trial is whether Signos specifically, or CGM-guided eating in non-diabetic adults generally, produces clinically meaningful weight loss superior to standard dietary advice.

Regulatory Standing and Legitimacy Checks

FDA Device Status

Signos itself is not a medical device and has no FDA clearance requirement as a software wellness app. The sensor it ships, the Abbott FreeStyle Libre 3, holds FDA 510(k) clearance K213332 [1]. The FDA's device database shows no recalls specific to the Libre 3 hardware as of January 2025. Separate from recalls, the MAUDE database does contain voluntary adverse-event reports related to Libre sensors generally, including skin reactions and inaccurate readings [2].

LegitScript and Pharmacy Regulation

LegitScript classifies and certifies online pharmacies and pharmacy-related businesses. Because Signos does not dispense controlled substances, compounded drugs, or prescription medications, it falls outside LegitScript's pharmacy certification scope. Its absence from LegitScript's certified list does not indicate any regulatory problem, it simply reflects that Signos is a wellness subscription company, not a pharmacy.

State Regulatory Actions

A search of state attorney general enforcement actions and state medical board actions through January 2025 returns no enforcement actions naming Signos directly. The company is headquartered in Los Altos, California and operates under California's health data privacy framework (CMIA), which provides stronger patient data protections than HIPAA alone in many scenarios [9].

What Users Report: App Store and Community Forums

App Store and Google Play Reviews

The Signos iOS app holds an approximate rating of 4.2 out of 5 across thousands of ratings on the Apple App Store as of early 2025. Positive reviews consistently highlight the glucose graph visualization, meal-tagging features, and the ability to see which foods cause personal spikes. Negative reviews cite app crashes during sensor pairing, delayed Bluetooth sync, and the absence of an Android-compatible version for older devices.

The Google Play rating is lower, approximately 3.6 out of 5, with a higher proportion of complaints about sensor connection stability on Android devices.

Reddit and Community Feedback

The r/Signos subreddit and broader CGM communities on r/loseit and r/diabetes_t2 contain a mix of enthusiastic and frustrated posts. Common themes among dissatisfied users:

• Expected faster weight loss than the app delivered
• Frustration that the "green zone" glucose targets felt arbitrary without physician input
• Concern that the subscription cost ($179 to $399 per month) was high relative to the perceived benefit after the first month

Common themes among satisfied users include discovering personal glucose triggers from specific foods (white rice, fruit juice, beer) that they had not anticipated, and using that information to make lasting dietary changes.

How Signos Compares to Clinical CGM Standards

Clinical CGM vs. Wellness CGM

In clinical diabetes care, CGM is used under physician supervision to adjust insulin dosing and detect hypoglycemia. The ADA's 2024 Standards of Care recommend real-time CGM for all adults with type 1 diabetes and for adults with type 2 diabetes using multiple daily insulin injections [10]. Those guidelines were written for a context where a clinician interprets the data and adjusts a medical treatment regimen.

Signos operates in a different context. No physician adjusts medications based on Signos data (because there are no medications in the Signos model). The app's algorithm interprets glucose patterns and makes dietary recommendations. Whether an algorithm can replace or approximate clinical judgment for a non-diabetic user is an open question that the current evidence base does not fully resolve.

MARD and Accuracy in Wellness Populations

The 9.2% MARD for the Libre 3 was validated primarily in adults with type 1 and type 2 diabetes who wore the sensor for calibration purposes [4]. Accuracy data in normoglycemic adults (fasting glucose <100 mg/dL) using Libre sensors is more limited. Some research suggests CGM accuracy may be somewhat lower at glucose levels below 70 mg/dL and in individuals with low glycemic variability, which describes many of the non-diabetic users Signos targets [11].

This does not make the sensor dangerous for wellness use, it means users and clinicians should interpret readings as trends rather than precise absolute values.

How to Evaluate Signos Before Subscribing

Key Questions to Ask

Before paying for a Signos subscription, a prospective user should consider these practical checkpoints:

1. Does your state's telehealth or weight-management guidelines recommend CGM for non-diabetic weight loss? Most do not require it, but some integrated obesity medicine practices do use it.
2. Have you confirmed your insurance covers Abbott Libre sensors for your use case? Most plans cover Libre only for diabetes diagnoses, meaning Signos users typically pay out-of-pocket.
3. Have you read the cancellation terms before entering payment information? The 30-day guarantee has conditions tied to sensor usage that the fine print specifies.

Red Flags vs. Expected Friction

Not every complaint is a red flag. Billing friction is common in subscription health products and does not by itself indicate fraud. The absence of FDA enforcement actions, state medical board sanctions, and LegitScript pharmacy violations means Signos is operating within the legal framework for a wellness subscription company.

A genuine concern would be if Signos made specific drug-equivalent efficacy claims (it does not), if its app provided insulin dosing recommendations (it does not), or if the company had a documented pattern of refusing to honor its stated refund policy. The BBB complaints suggest individual refund disputes rather than a systematic refusal to honor the guarantee.

Direct Comparison: Signos vs. Competing CGM Wellness Platforms

Several competitors occupy the same CGM-for-wellness space, including Levels Health and Nutrisense. All three use the Abbott Libre sensor system and charge comparable subscription fees. The primary differentiators are app interface design, the depth of coaching included, and community features.

None of these platforms have FDA clearance as a weight-loss treatment. All three have similar complaint profiles on the BBB and app stores, with billing and cancellation disputes appearing across all three brands at roughly comparable rates. Signos is neither uniquely problematic nor uniquely superior on consumer-complaint metrics compared to its direct competitors.

Clinical Bottom Line for Patients and Prescribers

Signos is a legitimate, legally operating wellness subscription company. Its hardware backbone is an FDA-cleared sensor with a 9.2% MARD that meets clinical accuracy standards for glucose trend monitoring [4]. Its complaint profile reflects subscription-economy friction and device accuracy limitations that are industry-wide rather than company-specific.

The clinical gap is the one that matters most: CGM-guided eating has mechanistic support, but no large randomized trial has shown that a CGM wellness subscription produces weight loss superior to structured dietary counseling alone in non-diabetic adults [6]. The ADA's 2024 Standards of Care do not recommend CGM for weight management in people without diabetes or prediabetes [10].

Clinicians recommending or discussing Signos with patients should frame it as a behavioral-feedback tool with plausible mechanism and limited outcomes evidence, not a substitute for pharmacotherapy (semaglutide, tirzepatide) or structured medical nutrition therapy in patients with obesity (BMI <30 with comorbidities or BMI <35).

Patients considering Signos should document their cancellation request with a timestamped screenshot and confirm receipt of a cancellation confirmation email before the next billing cycle closes.